Company overview
ORYL Photonics develops laser-based instruments for measuring solubility and aggregation of drug molecules and APIs in life sciences and pharma. Their patented light scattering technology, including the ORYL F1 platform, enables rapid, accurate, high-throughput analysis using minimal sample quantities. This Swiss EPFL spin-off supports R&D by reducing time and costs in formulation optimization.
ORYL Photonics is listed in the NovaPharmaNews Supplier Hub as a CDMO & Manufacturing, Lab Equipment & Instruments partner serving United States & Americas. Core focus areas include solubility measurement, drug aggregation, laser light scattering, pharma instruments, api characterization.
Industry categories: CDMO & Manufacturing, Lab Equipment & Instruments. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.orylphotonics.com
- Categories
- CDMO & Manufacturing, Lab Equipment & Instruments
- Markets served
- United States & Americas
- Keywords
- solubility measurement, drug aggregation, laser light scattering, pharma instruments, api characterization
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What instruments does ORYL Photonics offer for pharma R&D?
- ORYL Photonics offers the ORYL F1, an automated laser-based platform for ultrafast measurement of solubility and aggregation of drug molecules and APIs using minimal quantities.
- What technology powers ORYL Photonics' solutions?
- Their patented Solvent Redistribution method uses high-efficiency second harmonic light scattering from femtosecond lasers for sensitive, accurate results with low sample consumption.
- Where is ORYL Photonics located and what is their background?
- ORYL Photonics is a Swiss company founded in 2020 as an EPFL spin-off, based in Epalinges, Switzerland, focused on life sciences applications.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
